EUVIMEDEUVIMED entdecken
CrossrefInfokarte

2719-LB: Oral NLRP3 Inhibitor BGE-102 Preserves Retinal Vascular Integrity in a Preclinical Model of Diabetic Retinopathy

AIDEN EBLIMIT, DEAN PUNZALAN, SHIJUN YAN, ANDREW BANICKI, YAN WANG, KEVIN WILHELMSEN, CLAUDIA PORTILLO, MATTHEW BANICKI, MARY COCHRAN, CARL RODRIGUEZ, GEORGE HARTMAN, CHRISTOPHER PATIL, JUSTIN REBO, ROBERT HUGHES, RUSTY MONTGOMERY, ERIC MORGEN, KRISTEN FORTNEY, PAUL RUBIN

Diabetes · 2026-06-05 · 75 (Supplement_1)

DOI: 10.2337/db26-2719-lb ↗
AbstractBibliografische Angaben

Abstract

Introduction and Objective: Diabetic retinopathy (DR) is a leading cause of vision loss, but treatment relies largely on intravitreal therapies, resulting in suboptimal real-world outcomes. Hyperglycemia-driven NLRP3 inflammasome activation contributes to retinal vascular leakage, suggesting that oral NLRP3 inhibition could address this unmet need. We evaluated whether BGE-102, an oral, brain-penetrant NLRP3 inhibitor with therapeutic retinal exposure, could preserve retinal vascular integrity in a streptozotocin (STZ)-induced DR model. Methods: Male C57BL/6 mice received STZ (65 mg/kg IP × 5 days). Eleven days later, mice were randomized to vehicle, BGE-102 20 mg/kg, or BGE-102 50 mg/kg (PO QD; n=16-20/group) for 96 days alongside healthy controls. Retinal vascular permeability was assessed by fluorescein angiography (FA). Blood-retinal barrier integrity was evaluated by Claudin-5 immunohistochemistry (IHC). Fasting glucose and A1c were monitored. Data were analyzed by one-way ANOVA with Dunnett’s test. Results: All STZ groups developed sustained hyperglycemia (glucose ~300 mg/dL; A1c >8%) unaffected by BGE-102 at either dose. Despite persistent hyperglycemia, BGE-102 dose-dependently reduced retinal vascular permeability vs vehicle by 74% at 20 mg/kg and 98.7% at 50 mg/kg (both p<0.0001), with the higher dose restoring FA signal to healthy control levels. Claudin-5 IHC showed STZ reduced endothelial vascular content by 46% (p<0.01). BGE-102 restored tight junction integrity at both doses to 95% and 97% of healthy control levels (both p<0.01 vs vehicle). Conclusion: Oral BGE-102 preserved retinal vascular integrity and restored endothelial tight junctions in a DR model, with efficacy independent of glycemic control. These findings support NLRP3 inhibition as a novel approach to DR and the planned Phase 1b/2a trial in diabetic macular edema. Disclosure A. Eblimit: Employee; Current; BioAge Labs. D. Punzalan: Employee; Current; BioAge Labs. S. Yan: Employee; Current; BioAge LAbs. A. Banicki: Employee; Current; BioAge LAbs. Y. Wang: Employee; Current; BioAge Labs. K. Wilhelmsen: Employee; Current; BioAge Labs. C. Portillo: Employee; Current; BioAge Labs. M. Banicki: Employee; Current; BioAge Labs. M. Cochran: Employee; Current; BioAge Labs. C. Rodriguez: Employee; Current; BioAge Labs. G. Hartman: Employee; Current; BioAge Labs. C. Patil: Employee; Current; BioAge Labs. J. Rebo: Employee; Current; BioAge Labs. R. Hughes: Employee; Current; BioAge Labs. R. Montgomery: Employee; Current; BioAge Labs. E. Morgen: Employee; Current; BioAge Labs. Board Member; Current; BioAge Labs. Stock/Shareholder; Current; BioAge Labs. K. Fortney: Board Member; Current; BioAge Labs. Employee; Current; BioAge Labs. Stock/Shareholder; Current; BioAge Labs. P. Rubin: Employee; Current; BioAge Labs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →